Sanofi tops forecasts but Acomplia delay weighs
95372
Sanofi-Aventis posted higher than  expected fourth-quarter profits on Tuesday and predicted more  growth for 2007, but a further delay in its key new  anti-obesity drug Acomplia hit the shares.
670417
PARIS Sanofi-SynthÃ©labo, which this month completed its $63 billion purchase of a rival drug manufacturer, Aventis, reported Tuesday a 21 percent jump in first-half profit on higher demand for the blood thinner Plavix and the cancer treatment Eloxatin.
448727
Pharmaceutical group Sanofi-Synthelabo said it had increased net profit in the first half of the year by 20.6 percent from the same period last year to 1.138 billion euros (1.38 billion dollars).
680868
Sanofi-Aventis's anti-obesity drug Acomplia is facing three generic competitors in India even before it has won full approval from some markets, Les Echos newspaper reported on Thursday.
514994
Statistics from June mean more waiting for investors.
348260
PARIS  - The newly formed pharmaceutical group Sanofi-Aventis published third-quarter sales figures showing a 10.7 percent increase over 12 months in line with expectations.
233514
A new anti-obesity drug that works in the same way as Sanofi-Aventis's Acomplia has advanced in clinical trials, triggering a $25 million payment to Belgian drugs, chemicals and plastics maker Solvay.
738382
The drug maker is poised to speed past its rivals.
660854
Imperial Tobacco , which is looking to take over rival Altadis , met forecasts with a 12 percent rise in annual earnings on Tuesday, but a delay until January in completing the Altadis deal hit its shares.
335426
The newly formed pharmaceutical group Sanofi-Aventis published third-quarter sales figures showing a 10.7 percent increase over 12 months in line with expectations.
266489
A new drug from Sanofi-Aventis reduced  significantly episodes of atrial fibrillaton or irregular heart  beat in two clinical studies released on Sunday.
768602
Shares of Sanofi-Aventis SA, the world&#39;s third biggest drugmaker, may rise after research presented at Europe&#39;s largest medical meeting showed two of the company&#39;s new drugs may benefit heart patients.
167015
PARIS/LONDON  - Sanofi-Aventis shares rose on   Friday after a U.S. judge blocked further sales of generic   Plavix, but gains were capped as it warned cheap supplies of   the blood-thinner already in the market would hit 2006 profits.
675633
Sanofi-Aventis SA on Thursday said revenue rose 10.7 percent in the third quarter, as the company posted its first results since its creation from a tie-up between two French drug makers.
471639
Sanofi- Aventis SA's weight loss pill Acomplia shouldn't be approved in the United States because the company hasn't showed that the benefits outweigh the risk of suicidal thoughts among those taking the drug, an advisory panel said.
459566
LONDON/NEW YORK  - A court ruling upholding the patent on blockbuster blood-thinning drug Plavix has reignited talk France's Sanofi-Aventis  will bid for its smaller U.S. partner Bristol-Myers Squibb Co. .
50160
European stocks were slightly lower by mid-day in holiday-hit trading on Monday, with crude oil rises weighing on shares, though Sanofi-Aventis gained on the result of trials of an anti-obesity drug.